|Ms. Genevieve Lemaire||Interim Principal Financial Officer, Chief Accting Officer, VP of Fin. & Interim Corp Controller||210.16k||N/A||N/A|
|Dr. Richard Sachse M.D., Ph.D.||Chief Scientific Officer, Chief Medical Officer, Sr. VP and MD of Aeterna Zentaris GmbH||277.5k||N/A||N/A|
|Mr. Philip A. Theodore||Chief Admin. Officer, Sr. VP, Gen. Counsel and Corp. Sec.||384k||N/A||64|
|Mr. Jude Dinges||Chief Commercial Officer and Sr. VP||320k||N/A||N/A|
|Mr. David Alan Dodd||Chief Exec. Officer, Pres and Director||N/A||N/A||67|
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The companys product pipeline includes Zoptrex, which completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer, as well as in various phases for the treatment of ovarian and prostate cancer; and MACRILEN, which completed Phase III trial for use in the diagnosis of adult growth hormone deficiency. It is also developing an LHRH-disorazol Z conjugate, which is in pre-clinical development in oncology. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Summerville, South Carolina.
Aeterna Zentaris Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.